BRAF and metastatic melanoma: A recent multicenter, double-blind phase III trial (STARBOARD) of 624 patients with BRAF V600E/K metastatic melanoma compared the efficacy of triple therapy (encorafenib, binimetinib, and pembrolizumab) versus placebo plus PD-1 monotherapy (pembrolizumab).